How estrogen changes risk-taking in females
Investigation of the neurobiological mechanisms underlying estradiol-mediated risk aversion in females
This project looks at how the hormone estrogen alters decision-making and sensitivity to punishment in females, using animal models to learn about risks tied to substance use.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-11016984 on NIH RePORTER |
What this research studies
Researchers use a female rat model that shows greater caution to study how estradiol (a form of estrogen) and its receptors shape choices when there is a chance of punishment. They manipulate hormone levels and specific brain areas such as the amygdala, then measure how those changes affect risky versus safe decisions. The team also examines how prior drug exposure changes these hormone-brain interactions that control risk aversion. The aim is to reveal female-specific mechanisms that could guide better ways to reduce relapse and harmful risk-taking after substance use.
Who could benefit from this research
Good fit: Women with current or past substance use disorders, especially those concerned about impulsive or risky decision-making, are the group most likely to benefit from related clinical advances.
Not a fit: People without substance use concerns and men may not directly benefit from this female-focused animal research.
Why it matters
Potential benefit: If successful, this work could point to hormone-based or brain-directed strategies to reduce risky decisions and relapse in women with substance use disorders.
How similar studies have performed: Prior animal research has identified brain circuits for risk-taking (largely in males) and shown hormones can change behavior, but applying these findings to female-specific estradiol-driven risk aversion is relatively new.
Where this research is happening
Austin, United States
- University of Texas at Austin — Austin, United States (Active)
Researchers
- Principal investigator: Orsini, Caitlin Anne — University of Texas at Austin
- Study coordinator: Orsini, Caitlin Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.